Lancet Breast Cancer Commission Report Addresses Challenges to Reduce Disease Burden
Reshma Jagsi, MD, DPhil, highlights key takeaways from the Lancet Breast Cancer Commission Report and the necessary steps forward emphasized in the report.
Related Articles
Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML
Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.
A Promising Treatment for High-Risk Non-Muscle Invasive… : Oncology Times
An abstract is unavailable.
Help Fund an Early-Career Researcher
Eighty-eight cents of every dollar you give does directly to cancer research. Cancer Research Saves Lives.
Everyday Interactions, Extraordinary Impact: Moffitt McKinley Hospital Celebrates a Year of Serving Patients
A focus on outstanding care marks first year of memories at Moffitt McKinley Hospital
Home
Advanced Cancer Therapies serves as a comprehensive forum to promote research, development and application of advanced cancer therapies. This event promotes education and the exchange…
OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Sorafenib Plus Valproic Acid and Sildenafil Proves Active in High-Grade Glioma – Oncology Nurse Advisor
“Our data suggest that the combination of sorafenib tosylate, valproic acid, and sildenafil requires additional clinical development in the recurrent glioma population,” the researchers wrote.
Assessing Cosibelimab’s Future in Cutaneous Squamous Cell Carcinoma
According to Jason Luke, MD, FACP, there is still room to improve response rates in CSCC treatment, but there is excitement surrounding future of treatment…
Imlunestrant With or Without Abemaciclib Boosts PFS in ESR1+, ER+/HER2– Advanced Breast Cancer
Imlunestrant with or without abemaciclib improved PFS in select patients with ER-positive, HER2-negative advanced breast cancer after endocrine therapy.
Improving sickle cell nephropathy with concurrent GBT1118 & losartan treatment
Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, comments on the concurrent administration of GBT1118 & losartan in a mouse model of kidney disease…
